Date of Award

5-14-2023

Degree Type

Dissertation

Degree Name

Doctor of Philosophy (PhD)

Department

Chemistry

Advisor(s)

Robert Doyle

Second Advisor

Roy Welch

Abstract

Current treatments for type 2 diabetes mellitus (T2DM) and obesity do not reliably achieve long-termweight-loss and up to 50% of patients experience nausea and vomiting. Thus, there is a critical need for obesity medications that provide glycemic control with enhanced weight loss and without sideeffects. We recently reported on the development of EP45, a first in class monomeric peptide drug, which displayed glucoregulation and profound weight loss in rats, and an absence of visceral malaise in shrews, a mammalian model capable of vomiting (unlike rats). By targeting multiple weight-loss and glucoregulatory pathways simultaneously with a single drug, GEP44, we can address multiple coexisting conditions to more efficaciously reduce body weight and blood glucose levels, all devoid of side-effects to improve patient tolerance and quality of life.

Access

Open Access

Share

COinS